The potential use of histone deacetylase inhibitors in the treatment of depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 64, Issue , 2016, Pages 320-324

  Fuchikami, Manabu ^a   Yamamoto, Shigeto ^a   Morinobu, Shigeru ^b   Okada, Satoshi ^a   Yamawaki, Yosuke ^a   Yamawaki, Shigeto ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KOCHI UNIVERSITY   (Japan)

Author keywords

Antidepressant; Brain derived neurotrophic factor (BDNF); Depression; Histone deacetylase; Histone deacetylase (HDAC) inhibitor

Indexed keywords

BUTYRIC ACID; ENTINOSTAT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; ROMIDEPSIN; SILENT INFORMATION REGULATOR PROTEIN 2; VORINOSTAT; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; MAJOR DEPRESSION; NONHUMAN; PROTEIN EXPRESSION; SOCIAL AVOIDANCE BEHAVIOR; SOCIAL INTERACTION; SOCIAL STRESS; TRANSCRIPTION REGULATION; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; DEPRESSIVE DISORDER; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS;

EID: 84941179898     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.03.010     Document Type: Article

References (50)

1. Ashraf S.I., Ip Y.T. Transcriptional control: repression by local chromatin modification. Curr Biol 1998, 8:R683-R686.
2. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
3. Bilang-Bleuel A., Ulbricht S., Chandramohan Y., De Carli S., Droste S.K., Reul J.M. Psychological stress increases histone H3 phosphorylation in adult dentate gyrus granule neurons: involvement in a glucocorticoid receptor-dependent behavioural response. Eur J Neurosci 2005, 22:1691-1700.
4. Broide R.S., Redwine J.M., Aftahi N., Young W., Bloom F.E., Winrow C.J. Distribution of histone deacetylases 1-11 in the rat brain. J Mol Neurosci 2007, 31:47-58.
5. Chandramohan Y., Droste S.K., Arthur J.S., Reul J.M. The forced swimming-induced behavioural immobility response involves histone H3 phospho-acetylation and c-Fos induction in dentate gyrus granule neurons via activation of the N-methyl-d-aspartate/extracellular signal-regulated kinase/mitogen- and stress-activated kinase signalling pathway. Eur J Neurosci 2008, 27:2701-2713.
6. Covington H.E., Maze I., LaPlant Q.C., Vialou V.F., Ohnishi Y.N., Berton O., et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009, 29:11451-11460.
7. Covington H.E., Vialou V.F., LaPlant Q., Ohnishi Y.N., Nestler E.J. Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci Lett 2011, 493:122-126.
8. Drevets W.C. Orbitofrontal cortex function and structure in depression. Ann N Y Acad Sci 2007, 1121:499-527.
9. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:697-706.
10. Ferland C.L., Schrader L.A. Regulation of histone acetylation in the hippocampus of chronically stressed rats: a potential role of sirtuins. Neuroscience 2011, 174:104-114.
11. Fuchikami M., Morinobu S., Kurata A., Yamamoto S., Yamawaki S. Single immobilization stress differentially alters the expression profile of transcripts of the brain-derived neurotrophic factor (BDNF) gene and histone acetylation at its promoters in the rat hippocampus. Int J Neuropsychopharmacol 2009, 12:73-82.
12. Fujita Y., Morinobu S., Takei S., Fuchikami M., Matsumoto T., Yamamoto S., et al. Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene. J Psychiatr Res 2012, 46:635-643.
13. Gibson C.L., Murphy S.P. Benefits of histone deacetylase inhibitors for acute brain injury; a systematic review of animal studies. J Neurochem 2010, 115:806-813.
14. Goldberg A.D., Allis C.D., Bernstein E. Epigenetics: a landscape takes shape. Cell 2007, 128:635-638.
15. Gräff J., Tsai L.-H. The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol 2013, 53:311-330.
16. Grayson D.R., Kundakovic M., Sharma R.P. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?. Mol Pharmacol 2010, 77:126-135.
17. Greene J., Banasr M., Lee B., Warner-Schmidt J., Duman R.S. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009, 34:2459-2468.
18. Grozinger C.M., Chao E.D., Blackwell H.E., Moazed D., Schreiber S.L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001, 276:38837-38843.
19. Han S.-H. Potential role of sirtuin as a therapeutic target for neurodegenerative diseases. J Clin Neurol 2009, 5:120-125.
20. Han A., Sung Y.B., Chung S.Y., Kwon M.S. Possible additional antidepressant-like mechanism of sodium butyrate: targeting the hippocampus. Neuropharmacology 2014, 81:292-302.
21. Hisaoka K., Nishida A., Koda T., Miyata M., Zensho H., Morinobu S., et al. Antidepressant drug treatments induce glial cell line-derived neurotrophic factors (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 2001, 79:25-34.
22. Hobara T., Uchida S., Otsuki K., Matsubara T., Funato H., Matsuo K., et al. Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res 2010, 44:263-270.
23. Holliday R. Epigenetics: a historical overview. Epigenetics 2006, 1:76-80.
24. Hollis F., Wang H., Dietz D., Gunjan A., Kabbaj M. The effects of repeated social defeat on long-term depressive-like behavior and short-term histone modifications in the hippocampus in male Sprague-Dawley rats. Psychopharmacology (Berl) 2010, 211:69-77.
25. Iga J., Ueno S., Yamauchi K., Numata S., Kinouchi S., Tayoshi-Shibuya S., et al. Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 2007, 31:628-632.
26. Khochbin S., Verdel A., Lemercier C., Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 2001, 11:162-166.
27. Kramer O.H., Gottlicher M., Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 2001, 12:294-300.
28. Kurdistani S.K., Grunstein M. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 2003, 4:276-284.
29. Lieb J.D., Clarke N.D. Control of transcription through intragenic patterns of nucleosome composition. Cell 2005, 123:1187-1190.
30. Lin H., Geng X., Dang W., Wu B., Dai Z., Li Y., et al. Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex. Brain Res 2012, 1447:119-125.
31. Little A. Treatment-resistant depression. Am Fam Physician 2009, 80:167-172.
32. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
33. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
34. Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005, 16:4623-4635.
35. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
36. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734-36741.
37. Renthal W., Maze I., Krishnan V., Covington H.E., Xiao G., Kumar A., et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007, 56:517-529.
38. Rosenzweig-Lipson S., Beyer C.E., Hughes Z.A., Khawaja X., Rajarao S.J., Malberg J.E., et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007, 113:134-153.
39. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
40. Rush A.J., Trivedi M.H., Stewart J.W., Nierenberg A.A., Fava M., Kurian B.T., et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011, 168:689-701.
41. Schmauss C. An HDAC-dependent epigenetic mechanism that enhances the efficacy of the antidepressant drug fluoxetine. Sci Rep 2015, 5:8171.
42. Schroeder F.A., Lin C.L., Crusio W.E., Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 2007, 62:55-64.
43. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-525.
44. Uchida S., Hara K., Kobayashi A., Otsuki K., Yamagata H., Hobara T., et al. Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron 2011, 69:359-372.
45. Vecsey C.G., Hawk J.D., Lattal K.M., Stein J.M., Fabian S.A., Attner M.A., et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci 2007, 27:6128-6140.
46. Verdin E., Ott M. 50years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol 2014, [Epub ahead of priny]. 10.1038/nrm3931.
47. Walkinshaw D.R., Yang X.J. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 2008, 15:237-243.
48. West A.C., Johnstone R.W. New and emerging HDAC inhibitors for cancer treatment. J Clin Investig 2014, 124:30-39.
49. Yamawaki Y., Fuchikami M., Morinobu S., Segawa M., Matsumoto T., Yamawaki S. Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus. World J Biol Psychiatry 2012, 13:458-467.
50. Yasuda S., Liang M.H., Marinova Z., Yahyavi A., Chuang D.M. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 2009, 14:51-59.